RAPP vs RVMD Stock Comparison

RVMD currently leads RAPP in this stock comparison, with AIQ scores of 55 vs 43. The clearest difference is momentum, while RAPP has the stronger quality profile.

Market data as of Nov 15, 2026 market close· AIQ score gap 12 points
RAPP
Healthcare
vs
RVMD
Healthcare
RAPP
Rapport Therapeutics, Inc. Common Stock
Price
$26.15
Day move
+1.16%
AIQ Score
43/100
Best edge
Quality
Sector
Healthcare
RVMD
Revolution Medicines, Inc.
Leads
Price
$172
Day move
-2.3%
AIQ Score
55/100
Best edge
Momentum
Sector
Healthcare

What is the main difference between RAPP and RVMD?

RVMD leads the current stock comparison as Revolution Medicines, Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Rapport Therapeutics, Inc. Common Stock vs Revolution Medicines, Inc.

Data as of Nov 15, 2026· market close· Healthcare· Coverage 64/66 fields· High confidence
AIQ VerdictFragileAIQ Comparison Conviction 5/10

RVMD leads

RVMD leads by 12 AIQ points, primarily on Momentum and Risk Resilience, but the lead has narrowed from 19 points over 30 sessions. Wall Street currently favors RAPP on target upside.

Fragile: 3 of 6 evidence groups support RVMD, its lead is narrowing, and its current signal state is conflicted.

Evidence agreement: 3 of 6Comparison trend: Weakening
RAPP

Rapport Therapeutics, Inc. Common Stock

AIQ Score
43/100
AIQ Edge Score
3/10
RVMD

Revolution Medicines, Inc.

Leads
AIQ Score
55/100
AIQ Edge Score
5/10

The Algovestiq AIQ Score currently favors RVMD over RAPP, 55 versus 43 as of Nov 15, 2026. RVMD's advantage is driven primarily by stronger momentum and risk resilience, while RAPP holds the stronger quality profile. RVMD also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors RAPP. 3 of 6 covered evidence groups favor RVMD today, and the comparison is rated Fragile on stability: only 3 of 6 covered evidence groups agree. RVMD lead: Weakening — the AIQ differential moved from 19 to 12 points over 30 sessions.

Compare Rapport Therapeutics, Inc. Common Stock and Revolution Medicines, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

RAPP
+25.7%
RVMD
+327.1%

Price return comparison

Growth of $10,000, price only

RAPP $12,572 · RVMD $42,709

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare RAPP and RVMD against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

RAPP advantage
0
RVMD advantage
  • Momentum33 vs 73
    RVMD +40
  • Risk Resilience39 vs 59
    RVMD +20
  • Quality57 vs 43
    RAPP +14
  • Value42 vs 39
    Even

3 of 6 evidence groups favor RVMD. RVMD’s edge is concentrated in momentum and risk resilience; RAPP keeps a meaningful quality edge.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

RAPP0 AIQ

Largest factor move: Value +1, not enough on its own to move the overall score.

New signals

  • OBV Bullish Divergence — bullish, volume, medium horizon (-5.2%)
  • RSI Bullish Divergence — bullish, momentum, medium horizon
RVMD+1 AIQ

Largest factor move: Momentum +2

New signals

  • BB Lower Band Breach — bullish, volatility, short horizon
  • Stochastic Oversold Bounce — bullish, momentum, short horizon

RVMD's lead widened by 1 AIQ point in the latest session.

Deeper signal detail for each name lives on its own signals page — RAPP and RVMD both carry a full feed there.

The central trade-off

RVMD (Revolution Medicines, Inc.): the stronger current systematic profile, led by momentum and risk resilience.

RAPP (Rapport Therapeutics, Inc. Common Stock): the counter-case, on quality, fundamentals, analyst expectations — but at materially higher volatility, 111.1% against 71%.

The AIQ Score and Wall Street therefore point in different directions on this pair.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

RVMD

RVMD on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

RVMD

RVMD on combined revenue and EPS growth.

Value

Even

The two are level on Value.

Momentum

RVMD

RVMD on the Momentum factor, by 40 points.

Lower downside

RVMD

RVMD on Risk Resilience, by 20 points.

Analyst upside

RAPP

RAPP on implied upside to the consensus price target.

AIQ vs Wall Street

The model and the Street disagree here: AIQ favors RVMD, analyst targets favor RAPP. That disagreement is the most useful thing on this page.

MeasureRAPPRVMDNote
Implied upside to target+173.9%+52.3%RAPP has more room
Target dispersion+61.4%+53.7%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering1625Higher coverage generally improves confidence

The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

3 of 6 covered evidence groups favor RVMD. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreRVMD43 vs 55
FundamentalsRAPPon balancerevenue growth 0% vs 0%; EPS growth 29.4% vs 37.9%; TTM ROE -10.3% vs -17%; gross margin 100% vs 95.2%; operating margin -8.4% vs -8.5% — RAPP takes 2 of 3 decided legs, not all of them
ValuationEvenValue 42 vs 39
TechnicalsRVMDPrice vs 50-day -18.1% vs -11.4%; vs 200-day -26.5% vs 7.8%
Risk ResilienceRVMDRisk Resilience 39 vs 59
Analyst expectationsRAPPTarget upside 173.9% vs 52.3%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of RAPP and RVMD and are excluded from the count.

AIQ Decision Stability

Fragile

The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.

  • The AIQ gap is wide at 12 points. (supports the conclusion holding)
  • Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
  • The leader's advantage has been narrowing. (argues the conclusion is provisional)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on RVMD.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

RVMD lead: Weakening — the AIQ differential moved from 19 to 12 points over 30 sessions.

May 27RAPP leads above the line · RVMD leads belowNov 13
Today
RVMD +12
43 vs 55
7 sessions ago
RVMD +15
42 vs 57
30 sessions ago
RVMD +19
45 vs 64
90 sessions ago
RVMD +4
65 vs 69

The lead has not changed hands in this window.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

RAPPConflicted

2 bullish / 2 bearish / 1 neutral, conflicted

Only RAPP

  • Death Cross Active — bearish, trend, long horizon (11.45%)
  • Downtrend Structure Active — bearish, trend, long horizon
  • OBV Bullish Divergence — bullish, volume, medium horizon (-5.2%)
  • RSI Bullish Divergence — bullish, momentum, medium horizon
RVMDConflicted

3 bullish / 3 bearish / 1 neutral, conflicted

Only RVMD

  • Golden Cross Active — bullish, trend, long horizon (21.63%)
  • BB Lower Band Breach — bullish, volatility, short horizon
  • Beta Spike Warning — bearish, risk_regime, long horizon
  • Distribution Pattern — bearish, volume, medium horizon (1.12x)
  • MACD Histogram Expanding Bearish — bearish, momentum, short horizon
  • Stochastic Oversold Bounce — bullish, momentum, short horizon

Both carry 1 more signal that do not separate them: ATR Expansion - Breakout Mode.

RVMD leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

RAPPNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +1.16%, AIQ 0 points).

RVMDDivergence

Price is down while the AIQ Score moved up 1 points over the same session — price and model disagree (price -2.3%, AIQ +1 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1RAPP closes the Momentum gap — currently 40 points behind, the largest single contributor to RVMD's edge.
  2. 2RAPP's Death Cross Active resolves — a bearish trend rule currently active against it.
  3. 3RVMD's conflicting signal state resolves bearish — it currently carries 3 bullish and 3 bearish rules at once.
  4. 4The narrowing continues — the lead has already given back 7 points over 30 sessions, and a further 12-point move would eliminate RVMD's advantage entirely.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

RAPP leads on balance
MetricRAPPRVMD
Revenue growth (YoY)0%0%
EPS growth (YoY)29.4%37.9%
Gross margin100%95.2%
Operating margin-8.4%-8.5%
Return on equity (TTM)-10.3%-17%
Debt to equity0.020.27

Performance

RVMD leads 5 of 6 windows
MetricRAPPRVMD
1 week (5 sessions)7%-10.4%
1 month (20 sessions)-5.2%-3.2%
3 months (63 sessions)-46%-18.7%
6 months (126 sessions)-29.5%18.3%
Year to date-13.8%116.3%
1 year (252 sessions)3.9%161.7%

Technicals

RVMD has the stronger structure
MetricRAPPRVMD
RSI (14)44.939.7
ADX (14)31.417.6
Price vs 50-day-18.1%-11.4%
Price vs 200-day-26.5%7.8%
Volatility (1M, annualized)111.1%71%

Risk

RVMD is the more resilient
MetricRAPPRVMD
Beta1.271.3
Sharpe ratio0.351.69
Sortino ratio0.473.54
Max drawdown-57.1%-25%
Current drawdown-50.2%-22.1%
Annualized volatility62.3%68.7%
Value at risk (95%)-5.8%-4%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, RAPP or RVMD?

On the Algovestiq AIQ Score, RVMD is the stronger of the two as of Nov 15, 2026, scoring 55 against RAPP's 43. The edge comes from momentum and risk resilience. RAPP is not without a case — it holds the better quality profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is RAPP or RVMD the better buy right now?

RVMD carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 3 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: only 3 of 6 covered evidence groups agree. Treat the lead as provisional.

Why does the AIQ Score favor RVMD over RAPP?

The composite weights Quality, Value, Momentum and Risk Resilience. RVMD leads Momentum by 40 points; RVMD leads Risk Resilience by 20 points; RAPP leads Quality by 14 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, RAPP or RVMD?

Analyst price targets imply +173.9% upside for RAPP and +52.3% for RVMD, so the Street currently favors RAPP. That points the opposite way to the AIQ Score, which favors RVMD. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, RAPP or RVMD?

Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, RAPP or RVMD?

RVMD on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, RAPP or RVMD?

RVMD on the Momentum factor, by 40 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, RAPP or RVMD?

RVMD is the more resilient of the two, so the other name carries the higher downside risk. RVMD on Risk Resilience, by 20 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is RAPP more profitable than RVMD?

RAPP leads on the comparable margin measures — gross margin 100% vs 95.2%; operating margin -8.4% vs -8.5%; ttm roe -10.3% vs -17%.

Is RVMD's lead over RAPP getting stronger or weaker?

RVMD lead: Weakening — the AIQ differential moved from 19 to 12 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.

What would change the RAPP vs RVMD verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: RAPP closes the Momentum gap — currently 40 points behind, the largest single contributor to RVMD's edge; RAPP's Death Cross Active resolves — a bearish trend rule currently active against it; RVMD's conflicting signal state resolves bearish — it currently carries 3 bullish and 3 bearish rules at once; the narrowing continues — the lead has already given back 7 points over 30 sessions, and a further 12-point move would eliminate RVMD's advantage entirely.

What do the current signals say about RAPP and RVMD?

RAPP: 2 bullish / 2 bearish / 1 neutral, conflicted. RVMD: 3 bullish / 3 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on RAPP is Death Cross Active (bearish, long horizon). On RVMD it is Golden Cross Active (bullish, long horizon).

Compare RAPP and RVMD with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.